Galapagos NV (NASDAQ:GLPG) is Finepoint Capital LP’s 10th Largest Position

Finepoint Capital LP lifted its holdings in Galapagos NV (NASDAQ:GLPG) by 2.8% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 557,762 shares of the biotechnology company’s stock after buying an additional 15,000 shares during the period. Galapagos makes up about 1.2% of Finepoint Capital LP’s portfolio, making the stock its 10th biggest holding. Finepoint Capital LP’s holdings in Galapagos were worth $16,058,000 at the end of the most recent quarter.

Several other hedge funds have also recently made changes to their positions in GLPG. Headlands Technologies LLC grew its position in Galapagos by 56.7% in the second quarter. Headlands Technologies LLC now owns 1,233 shares of the biotechnology company’s stock worth $31,000 after acquiring an additional 446 shares in the last quarter. GAMMA Investing LLC lifted its stake in shares of Galapagos by 140.7% in the 3rd quarter. GAMMA Investing LLC now owns 1,259 shares of the biotechnology company’s stock valued at $36,000 after purchasing an additional 736 shares during the last quarter. Signaturefd LLC boosted its holdings in shares of Galapagos by 48.1% in the 2nd quarter. Signaturefd LLC now owns 3,872 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 1,258 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Galapagos by 63.2% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,899 shares of the biotechnology company’s stock valued at $112,000 after purchasing an additional 1,510 shares during the last quarter. Finally, Rhumbline Advisers raised its holdings in Galapagos by 21.6% during the 2nd quarter. Rhumbline Advisers now owns 4,578 shares of the biotechnology company’s stock valued at $113,000 after buying an additional 814 shares during the period. 32.46% of the stock is currently owned by hedge funds and other institutional investors.

Galapagos Trading Up 0.7 %

GLPG stock opened at $27.31 on Tuesday. The firm has a 50 day moving average of $28.62 and a 200 day moving average of $27.49. Galapagos NV has a 52 week low of $24.16 and a 52 week high of $42.46.

Wall Street Analysts Forecast Growth

GLPG has been the topic of a number of recent analyst reports. Kepler Capital Markets lowered shares of Galapagos from a “hold” rating to a “reduce” rating in a research report on Wednesday, November 20th. Leerink Partners started coverage on Galapagos in a research report on Monday, September 9th. They set a “market perform” rating and a $24.00 price target on the stock. Leerink Partnrs upgraded shares of Galapagos to a “hold” rating in a research note on Monday, September 9th. Royal Bank of Canada dropped their price objective on Galapagos from $32.00 to $30.00 and set a “sector perform” rating on the stock in a research report on Friday, November 1st. Finally, Raymond James cut shares of Galapagos from an “outperform” rating to a “market perform” rating in a research report on Friday, August 2nd. Two analysts have rated the stock with a sell rating and six have given a hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $30.75.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.